Market Overview

UPDATE: Jefferies Raises PT on Eli Lilly & Co. as Least-Preferred Name

Related LLY
Benzinga's Top Upgrades
Credit Suisse Upgrades Eli Lilly; Likes Jardiance For Short-Term And Pipeline For Long-Term
Eli Lilly (Investor's Business Daily)

In a report published Wednesday, Jefferies analyst Jeffrey Holford reiterated an Underperform rating on Eli Lilly & Co. (NYSE: LLY), and slightly raised the price target from $43.00 to $44.00.

In the report, Holford noted, “We remain positive on Pharmaceuticals and see valuation as attractive for most stocks. Our Top Pick in the US is AbbVie, with Novartis being our most preferred name in Europe. Sanofi, Roche and Pfizer remain high conviction Buy ratings. We point to Eli Lilly and GlaxoSmithKline as least preferred names.”

Eli Lilly & Co. closed on Tuesday at $56.74.

Latest Ratings for LLY

Oct 2015Credit SuisseUpgradesNeutralOutperform
Sep 2015JP MorganMaintainsNeutral
Sep 2015JefferiesMaintainsBuy

View More Analyst Ratings for LLY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings


Related Articles (LLY)

Get Benzinga's Newsletters